Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA ; day:7 ; month:4 ; year:2022 ; pages:1-12
Investigational new drugs ; (7.4.2022), 1-12
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-022-01227-5
- URN
-
urn:nbn:de:101:1-2022062506544981388811
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:35 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Michaeli, Daniel
- Mills, Mackenzie
- Michaeli, Christoph T.
- Miracolo, Aurelio
- Kanavos, Panos
- SpringerLink (Online service)
Ähnliche Objekte (12)
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
TGA
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA
FDA
FDA
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
TGA
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA
FDA
FDA
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
TGA
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA
FDA